Earnings Analysis July 30, 2026

Cigna Group ($CI) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Both Top Estimates, Full-Year Guidance Edged Up

Earnings Scorecard

Revenue: $71.668 billion (up 7% year over year; estimate $70.183 billion) ✅ Beat

EPS: Adjusted basis $7.78 (estimate $7.60) ✅ Beat

Guidance: Raised — 2026 full-year adjusted operating income per share of at least $30.45 (up $0.10 from prior outlook)

Stock reaction: After-hours -1.17% ($293) — as of 07-30 21:01 KST

The Positives

Revenue and earnings both topped estimates: Adjusted EPS of $7.78 and revenue of $71.668 billion beat consensus

Sharp jump in insurance-segment earnings: Cigna Healthcare's pre-tax adjusted income rose 17% year over year

Full-year guidance raised: 2026 adjusted operating income per share lifted to at least $30.45

Global healthcare company Cigna Group ($CI) posted Q2 total revenue of $71.668 billion, up 7% from $67.178 billion a year earlier and above the $70.183 billion the market had expected. Adjusted operating-income EPS came in at $7.78, up from $7.20 a year earlier and ahead of the $7.60 analyst consensus. GAAP EPS was $6.29.

The growth engine was Cigna Healthcare. Adjusted revenue rose 9%, pre-tax adjusted income climbed 17%, and the company cited improved U.S. employer insurance margins. Within Evernorth Health Services, pre-tax adjusted income from specialty pharmacy and care services jumped 22%, reflecting expanded specialty drug volumes and the broader spread of generics and biosimilars. Medical customers rose 2% from year-end to 18.41 million, and cost efficiency improved on a lower SG&A ratio, among other areas.

The Negatives

Sharp drop in pharmacy benefits earnings: Pre-tax adjusted income at pharmacy benefits services fell 27% year over year

Medical loss ratio deteriorated: Medical loss ratio of 84.5%, up from 83.2% a year earlier

Pharmacy customer attrition: Total pharmacy customers of 118.2 million, down 4% from year-end

Evernorth's adjusted revenue rose 6%, but pre-tax adjusted income slipped 2%. In particular, pharmacy benefits (drug-benefit) services earnings tumbled sharply due to the renewal of large client contracts and client-centric initiatives. Although revenue grew 8% on a mix shift, the decline in profitability was steeper, leaving a visible gap between revenue and earnings.

Cigna Healthcare's medical loss ratio rose to 84.5% from 83.2% a year earlier. The company attributed the move to a base effect from risk-adjustment benefits recognized in last year's Q2 within individual and family insurance, but the impression of heavier underwriting costs remains. The decline in pharmacy customers was attributed to anticipated client transitions and a reduction in health-plan enrollees, and the decision to exit the individual and family medical insurance business from January 2027 is another medium-term portfolio variable.

What the Company Said

Management emphasized that the strategy of leveraging technology, data, and AI to drive personalized experiences and cost savings was validated by Q2 results. The tone was confident, and the raise of full-year adjusted operating income guidance to at least $30.45 per share supported that confidence. However, with the raise limited to $0.10, the bar was not lifted dramatically for what was a "strong quarter."

By segment, Cigna Healthcare's pre-tax adjusted income guidance was raised by $25 million to at least $4.55 billion, with the full-year medical loss ratio target set at 83.7% to 84.7%. Evernorth's pre-tax adjusted income guidance is at least $6.9 billion. The market acknowledged the beats and modest guidance raise, but the read is that it wants to see whether the pressure on pharmacy benefits earnings persists into the second half and whether underwriting costs stabilize near the upper end of the guidance range.

Market Reaction and Forward Watchpoints

Even with both adjusted EPS and revenue beating expectations and guidance lifted, after-hours trading stayed roughly flat to slightly lower. Rather than the "beat" itself, the market appears to have focused first on the 27% drop in pharmacy benefits earnings, the deterioration in the medical loss ratio, and the modest size of the guidance raise. Against a backdrop where strong results were already largely priced in, the interpretation that the market read the qualitative soft spots more sensitively is compelling.

Watch whether pharmacy benefits services margins emerge from the impact of large contract renewals and recover.

Track whether the medical loss ratio stabilizes within the full-year target of 83.7% to 84.7%, and whether the improved U.S. employer insurance margin is sustained.

Assess the impact on Healthcare's earnings structure of the 2027 exit from individual and family insurance, and monitor net medical customer growth.